An interventional study of Biospecimen Collection and Biospecimen Collection in Glioblastoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Diagnostic
Among 23 studies in Glioblastoma by City of Hope Medical Center — 6 open to participants now, 12 under way, none of them phase 3. Glioblastoma · City of Hope Medical Center.
Among the 23 studies in Glioblastoma by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 22 interventional ones, is one of 2 that started in 2026, is the only one with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 23rd registered.
2,132 studies on the registry are indexed under Glioblastoma; 464 are open to participants now.
This study's planned enrollment of 30 is below the median of 36 across 1,753 interventional studies indexed under Glioblastoma.
Browse Glioblastoma studies →6 of the 23 studies in Glioblastoma by City of Hope Medical Center are open now, in 1 country. Each count lists the studies.
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →23 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
Median enrollment 19 across the 22 interventional studies, 160 across the 1 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
4 of the studies in Glioblastoma by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03389230City of Hope Medical CenterMemory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | 2026-12-29 |
| NCT07664579City of Hope Medical CenterInvestigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | 2027-01-04 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT04214392City of Hope Medical CenterChimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | 2027-05-11 |
Among the 23 studies in Glioblastoma by City of Hope Medical Center, from their registry updates:
This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid. If tears are found to contain similar tumor-related particles, changes in the tumor may be tracked by studying the particles found in tear fluid.
PRIMARY OBJECTIVE:
I. To assess the feasibility of tear collection from healthy control and glioblastoma (GBM) patients (Phase 1 and 2).
SECONDARY OBJECTIVES:
I. To assess the feasibility of isolating and analyzing tumor-associated extracellular vesicles (TEVs) from tears of GBM patients (Phase 1 and 2).
II. To characterize the composition of tear-derived extracellular vesicles (EVs).
EXPLORATORY OBJECTIVES:
I. To compare EV profiles between patients with GBM and healthy control participants (Phase 1 and 2).
II. To explore longitudinal changes in EV profiles of patients from tears, CSF and plasma (Phase 2), and their association with clinical disease status, including radiographic response and recurrence.
III. To explore concordance between EV profiles and matched tumor molecular pathology as determined by HopeSeq analysis (Phase 2).
OUTLINE: Patients are assigned to 1 of 2 phases.
PHASE 1: Patients and healthy controls undergo collection of tears on study.
PHASE 2: Patients and healthy controls undergo collection of tears and blood samples and patients undergo collection of standard of care CSF samples throughout the study.
After completion of study intervention, patients are followed for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients and healthy controls undergo collection of tears on study.
Procedure: Biospecimen Collection · Other: Electronic Health Record Review · Other: Questionnaire Administration
Patients and healthy controls undergo collection of tears and blood samples and patients undergo collection of standard of care CSF samples throughout the study.
Procedure: Biospecimen Collection · Other: Electronic Health Record Review · Other: Questionnaire Administration
Undergo collection of tears
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo collection of blood and standard of care CSF samples
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Ancillary studies
Ancillary studies
Proportion of samples containing at least 2 uL of tear (feasibility)
An exact two-sided 95% confidence interval will be provided as a measure of precision. P-values and confidence intervals will be interpreted descriptively.
Time frame: Up to 2 years
Quality and integrity of tear-derived extracellular vesicles (EVs)
Will be assessed by the ability to generate interpretable SEVEN imaging data with acceptable signal-to-noise characteristics and vesicle morphology consistent with intact vesicles. Assay linearity will be evaluated using a dilution series.
Time frame: Up to 2 years
Successful detection and quantification of tear-derived tumor-associated EVs (TEVs)
Will be evaluated using the SEVEN platform, including measurable TEV abundance and detection of glioblastoma-associated markers. Assay linearity will be evaluated using a dilution series.
Time frame: Up to 2 years
Characterization of the protein composition of tear-derived EVs
Will include detection and relative quantification of central nervous system tumor-associated proteins using enzyme-linked immunosorbent assay. Will be descriptively summarized.
Time frame: Up to 2 years
Detection of tumor-associated genetic and epigenetic alterations
Will be determined by polymerase chain reaction-based sequencing methods within tear-derived EVs. Will be descriptively summarized.
Time frame: Up to 2 years
Started Oct 2026 (actual). Primary completion is estimated for Feb 2029, 27 months after the start.
Of 131 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 27 months is below that.
Counting every sponsor, half of 149 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 30, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Feb 2029, on Oct 8, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Feb 2029, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.